Company Profile
Vivani Medical Stock Price, News & Analysis
- Ticker:
- VANI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.36 USD (-1.45%)
Close
Last updated: August 6, 2026
112M USD
Market cap
Why the stock is moving
The latest company update was “Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight…”. VANI changed 1.45% and closed at $1.36 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this clinical readout update.
Company overview
Long-Acting Implant Company
Vivani Medical develops miniature drug implants intended to provide multi-month delivery of established medicines.
NanoPortal Technology
The NanoPortal platform controls drug diffusion through a compact implant, with the goal of improving adherence and reducing treatment burden.
NPM-139
NPM-139 is an ultra-long-acting semaglutide implant for chronic weight management and the lead program in Vivani’s SLIM clinical platform.
Future catalysts
The Phase 1 SLIM-1 study of NPM-139 is expected to begin around mid-2026.
Topline SLIM-1 results are projected by year-end 2026.
Vivani plans an IND submission supporting a Phase 2 dose-ranging study of NPM-139 in 2027.
Recent news
- 01
- 02
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Source: Vivani Medical
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vivani Medical (VANI)?
Vivani Medical (VANI) most recently closed at 1.36 USD, a -1.45% move versus the previous session.
What is the market cap of Vivani Medical (VANI)?
Vivani Medical currently has a market capitalization of 112M USD on BioPharmSignal.
What does Vivani Medical do?
Long-Acting Implant Company Vivani Medical develops miniature drug implants intended to provide multi-month delivery of established medicines. NanoPortal Technology The NanoPortal platform controls drug diffusion through a compact implant, with the goal of improving adherence and reducing treatment burden. NPM-139 NPM-139 is an ultra-long-acting semaglutide...
On which exchange is VANI stock listed?
Vivani Medical (VANI) is associated with NASDAQ, United States, Biopharma.
What is NPM-139?
The Phase 1 SLIM-1 study of NPM-139 is expected to begin around mid-2026.
Which conditions is Vivani Medical targeting with NPM-139?
The Phase 1 SLIM-1 study of NPM-139 is expected to begin around mid-2026.
How does Vivani Medical describe recent progress with NPM-139?
The Phase 1 SLIM-1 study of NPM-139 is expected to begin around mid-2026.
What is SLIM-1?
The Phase 1 SLIM-1 study of NPM-139 is expected to begin around mid-2026.